

| | | Single ASCT (N=286) | | 1. Part Tandem ASCT (N=34) | | 2. Part Tandem ASCT (N=34) | |
|--|---------------------------|------------------------|----------|----------------------------------|----------|----------------------------------|---------|
| | | No. | % | No. | % | No. | % |
| Stem cell mobilization therapy | available | 245 | 86 | 34 | 100 | * | |
| | unavailable | 41 | 14 | 0 | 0 | | |
| | IEV | 168 | 69 | 23 | 68 | | |
| | CA | 15 | 6 | 0 | 0 | | |
| | C | 36 | 15 | 7 | 20 | | |
| | SS | 26 | 10 | 4 | 12 | | |
| No. of collected CD34 ⁺ cells (x10 ⁶ per kg body weight) | median/range | 11.0 | 2.9-113 | 13.5 | 4.0-28.0 | | |
| No. of transfused CD34 ⁺ cells (x10 ⁶ per kg body weight) | median/range | 4.62 | 1.3-12.7 | 3.74 | 1.4-9.1 | 4.0 | 1.9-9.1 |
| Melphalan dosage (mg/m ²) | available | 246 | 86 | 33 | 97 | 33 | 97 |
| | unavailable | 40 | 14 | 1 | 3 | 1 | 3 |
| | 200 | 186 | 76 | 27 | 82 | 25 | 76 |
| | 140 | 51 | 20 | 3 | 9 | 5 | 15 |
| | 100 | 9 | 4 | 3 | 9 | 3 | 9 |
| | | | | | | | |
| Complications - per patient | available | 197 | 69 | 24 | 71 | 25 | 74 |
| | unavailable | 89 | 31 | 10 | 29 | 9 | 26 |
| | yes | 145 | 74 | 15 | 63 | 18 | 72 |
| | no | 52 | 26 | 9 | 38 | 7 | 28 |
| Complications total | <2 complications | 65 | 33 | 6 | 25 | 4 | 16 |
| | Mucositis grade III/IV | 82 | 42 | 6 | 25 | 6 | 24 |
| | Febrile neutropenia | 67 | 34 | 7 | 29 | 10 | 40 |
| | Bacteremia | 9 | 5 | 2 | 8 | 2 | 8 |
| | TRD** | 8 | 3 | 0 | 0 | 1 | 3 |
| | Other | 33 | 17 | 4 | 17 | 3 | 12 |
| Nadir, days post-ASCT | median days/range | 6 | 3-10 | 5 | 4-7 | 5 | 3-6 |
| Neutrophil engraftment (>0.5x10 ⁹ /l, days post ASCT) | median days/range | 12 | 6-23 | 12 | 10-17 | 11 | 10-16 |
| Platelet engraftment (>50 x 10 ⁹ /l, days post- ASCT) | median days/range | 14 | 8-43 | 13 | 12-18 | 16 | 14-17 |
| Platelet engraftment reached | available | 221 | 77 | 11 | 32 | 31 | 91 |
| | unavailable | 65 | 23 | 23 | 68 | 3 | 9 |
| | yes | 103 | 47 | 6 | 55 | 5 | 16 |
| | no | 118 | 53 | 5 | 45 | 26 | 84 |

Supplemental Table 1. Patient characteristics at single and tandem ASCT

IEV, ifosfamide/epirubicin/etoposide; CA, cyclophosphamide/adriamycin; C, cyclophosphamide; SS, steady-state mobilization; TRD, treatment related death; * stem cell mobilization therapy and collection only performed before part one of tandem ASCT; **TRD was determined as death from any cause other than progression or relapse before day +100 from last ASCT in patients with a follow-up of ≥100 days after last ASCT; available, detailed information available.